MedPharm are Finalists at CPhI Pharma Awards 2019

MedPharm is pleased to announce that we have been shortlisted for an award at this year’s CPhI Pharma Awards. We are excited to be selected as finalists for ‘Excellence in Pharma: Analysis, Testing, and Quality Control’.

CPHI Pharma

This year MedPharm have been recognized for their involvement in pioneering the regulatory approval of topical products using in vitro bioequivalence to replace expensive clinical trials.

These clinical trials are expensive and risky which has created a major barrier to generic entry. Consequently, many originators remain the only product on the market after their patent expiry.

MedPharm is the first contract research organization to gain regulatory approval using in vitro models to demonstrate the bioequivalence of a generic formulation compared to the originator. MedPharm has developed robust statistical justification using multiple donors to demonstrate bioequivalence to the satisfaction of regulatory authorities.

The ultimate winner is the patient who can benefit from more cost-effective topical therapy.

The awards will take place on 5th November during the annual CPhI Worldwide conference that MedPharm will also be attending. We hope to see you there to celebrate not just our success, but the excellence across our industry. Please follow this link to learn how you can attend this gala.

Notes to editors

About MedPharm
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm is experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognized for their scientific rigor by regulators and investors. MedPharm has fully established R&D centers in the USA and UK and has its global HQ in Guildford, UK.